Population
46 patients with giant cell myocarditis (31 women, mean age 51 ± 12 years)
Design
Cohort
Follow-up
median 11 months
Authors
Loading...
Supports risk stratification in giant cell myocarditis; hypothesis-generating and requires prospective validation before guiding care.
In giant cell myocarditis, 5-year transplant-free survival is 42%, with markers of myocyte injury (troponin, NT-proBNP, biopsy necrosis/fibrosis) and cardiac dysfunction (LVEF) predicting worse outcomes.
Ekström et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: